LEADER 00827nam0-22003011i-450- 001 990000895580403321 005 20001010 035 $a000089558 035 $aFED01000089558 035 $a(Aleph)000089558FED01 035 $a000089558 100 $a20001010d--------km-y0itay50------ba 101 0 $aita 105 $ay-------001yy 200 1 $aConnections Studies in Building Assemblay 210 $aOxford$cButterworth Heinemann$d1992 215 $ap.128$cill.$dcm30 610 0 $aCostruzioni Metalliche 700 1$aBrookes,$bAlan$f<1939- >$010629 702 1$aGrech,$bC. 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990000895580403321 952 $a03 CM.0,237$b587$fIINTC 959 $aIINTC 996 $aConnections Studies in Building Assemblay$9356998 997 $aUNINA DB $aING01 LEADER 03786nam 22006375 450 001 9911031666003321 005 20251001130613.0 010 $a3-032-06908-4 024 7 $a10.1007/978-3-032-06908-5 035 $a(MiAaPQ)EBC32323712 035 $a(Au-PeEL)EBL32323712 035 $a(CKB)41528763800041 035 $a(DE-He213)978-3-032-06908-5 035 $a(EXLCZ)9941528763800041 100 $a20251001d2025 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aBreast Cancer Immunotherapy /$fedited by Marcus Schmidt, Rita Nanda 205 $a1st ed. 2025. 210 1$aCham :$cSpringer Nature Switzerland :$cImprint: Springer,$d2025. 215 $a1 online resource (374 pages) 225 1 $aCancer Immunotherapy,$x2662-8392 ;$v3 311 08$a3-032-06907-6 327 $aPart I: Immunity and Cancer -- The Functional Cancer Immunity Cycle -- Rationale for Immunotherapy for Breast Cancer -- Tumor-Infiltrating Lymphocytes as a Prognostic and Predictive Marker in Breast Cancer -- Part II: Therapeutic Interventions for Breast Cancer -- Therapeutic Interventions for Breast Cancer: Advanced Breast Cancer -- Immunotherapy in Early Triple-Negative Breast Cancer -- Part III: Vaccines -- Peptide Vaccines in Breast Cancer -- mRNA Vaccination for Breast Cancer -- Part IV: Emerging Therapeutic Strategies -- Radiation and Immunotherapy in Breast Cancer -- The Clinical Development of Immune Checkpoint Inhibitors in Combination with Targeted Therapy in Breast Cancer -- Targeting the STING Pathway in Breast Cancer -- Immunotherapy Combinations and Dual Checkpoint Blockade -- CAR T Cell Strategies for Metastatic Breast Cancer -- Part V: Emerging Biomarkers of Response to Immunotherapy -- Tumor Characteristics -- Host Characteristics in Breast Cancer. 330 $aThis comprehensive book presents the most up-to-date and innovative information on the immunotherapy of breast cancer. The book opens by providing an introduction to mechanisms of the immune system in cancer, including the principles of immunoediting and the cancer-immunity cycle. After discussion of the prognostic and predictive roles of the immune system in breast cancer, attention is turned to successful therapeutic strategies. The use of monoclonal antibodies is thoroughly described, and a particular focus of the book is the use of checkpoint inhibitors to strengthen the immune system by releasing its brakes, this being an area of growing importance. In addition, novel vaccination strategies in breast cancer and early treatment concepts using chimeric antigen receptor (CAR) T cells are covered in depth. The book concludes by examining future prospects in the field. Written by international experts in the topics that they address, Breast Cancer Immunotherapy will be a valuable update for researchers and clinical practitioners alike. 410 0$aCancer Immunotherapy,$x2662-8392 ;$v3 606 $aImmunotherapy 606 $aInternal medicine 606 $aImmunology 606 $aGynecology 606 $aImmunotherapy 606 $aInternal Medicine 606 $aImmunology 606 $aGynecology 615 0$aImmunotherapy. 615 0$aInternal medicine. 615 0$aImmunology. 615 0$aGynecology. 615 14$aImmunotherapy. 615 24$aInternal Medicine. 615 24$aImmunology. 615 24$aGynecology. 676 $a615.37 676 $a571.96 700 $aSchmidt$b Marcus$01850979 701 $aNanda$b Rita$01850980 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9911031666003321 996 $aBreast Cancer Immunotherapy$94444189 997 $aUNINA